Related Experiment Video
Updated: Dec 26, 2025

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies
Published on: January 4, 2015
Neural stem cell-conditioned medium ameliorates Aβ25-35-induced damage in SH-SY5Y cells by protecting mitochondrial
Guoyong Jia1, Zengyan Diao1, Ying Liu1
1Department of Neurology, Qilu Hospital, Shandong University, Jinan, China.
Abstract:
Inhibition of amyloid β (Aβ)-induced mitochondrial damage is considered crucial for reducing the pathological damage in Alzheimer's disease (AD). We evaluated the effect of neural stem cell-conditioned medium (NSC-CDM) on Aβ25-35-induced damage in SH-SY5Y cells. An in vitro model of AD was established by treating SH-SY5Y cells with 40 µM Aβ25-35 for 24 h. SH-SY5Y cells were divided into control, Aβ25-35 (40 µM), Aβ25-35 (40 µM) + NSC-CDM, and Aβ25-35 (40 µM) + neural stem cell-complete medium (NSC-CPM) groups. Cell viability was detected by CCK-8 assay. Apoptosis, reactive oxygen species (ROS) production, and mitochondrial membrane potential (MMP) were detected by flow cytometry. Malondialdehyde content was detected by ELISA assay. Western blot analysis was used to detect cytochrome c release and apoptosis-related proteins. Transmission electron microscopy was used to observe mitochondrial morphology. Cell viability significantly decreased and apoptosis significantly increased in SH-SY5Y cells treated with Aβ25-35, and both effects were rescued by NSC-CDM. In addition, NSC-CDM reduced ROS production and significantly inhibited the reduction of MMP caused by Aβ25-35. Furthermore, NSC-CDM ameliorated Aβ25-35-induced reduction in Bcl-2 expression levels and increased the expression levels of cytochrome c, caspase-9, caspase-3, and Bax. Moreover, Aβ25-35 induced the destruction of mitochondrial ultrastructure and this effect was reversed by NSC-CDM. Collectively, our findings demonstrated the protective effect of NCS-CDM against Aβ25-35-induced SH-SY5Y cell damage and clarified the mechanism of action of Aβ25-35 in terms of mitochondrial maintenance and mitochondria-associated apoptosis signaling pathways, thus providing a theoretical basis for the development of novel anti-AD treatments.
Insights
Neural stem cell-conditioned medium (NSC-CDM) protects against Alzheimer's disease (AD) by preventing amyloid-beta (Aβ)-induced mitochondrial damage and cell death in neuronal cells. This study highlights NSC-CDM as a potential therapeutic strategy for AD.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Alzheimer's disease (AD) pathology involves amyloid-beta (Aβ) aggregation and subsequent mitochondrial dysfunction.
- Inhibiting Aβ-induced mitochondrial damage is a key therapeutic target for AD.
- Neural stem cell-conditioned medium (NSC-CDM) is being explored for its neuroprotective potential.
Purpose of the Study:
- To evaluate the protective effects of NSC-CDM against Aβ25-35-induced damage in SH-SY5Y neuroblastoma cells.
- To elucidate the mechanisms underlying NSC-CDM's neuroprotection, focusing on mitochondrial integrity and apoptosis pathways.
Main Methods:
- An in vitro AD model was created using Aβ25-35 treatment of SH-SY5Y cells.
- Cell viability (CCK-8), apoptosis, reactive oxygen species (ROS), and mitochondrial membrane potential (MMP) were assessed via flow cytometry.
- Malondialdehyde (MDA) levels, cytochrome c release, apoptosis-related proteins (Bcl-2, Bax, Caspase-3, Caspase-9), and mitochondrial ultrastructure (TEM) were analyzed.
Main Results:
- Aβ25-35 significantly reduced cell viability and increased apoptosis, which were reversed by NSC-CDM treatment.
- NSC-CDM mitigated Aβ25-35-induced increases in ROS and MDA, and prevented the reduction of MMP.
- NSC-CDM normalized the expression of apoptosis-related proteins and preserved mitochondrial ultrastructure against Aβ25-35 damage.
Conclusions:
- NSC-CDM demonstrates significant neuroprotective effects against Aβ25-35-induced cellular damage in an in vitro AD model.
- The protective mechanism involves maintaining mitochondrial function and inhibiting mitochondria-mediated apoptosis.
- These findings support NSC-CDM as a promising therapeutic candidate for Alzheimer's disease treatment.

